Age >75 + ECOG ≥2 OR significant comorbidity — pentostatin's weekly schedule allows finer...
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | RF-HCL-FRAILTY-AGE |
|---|---|
| Art | Warnhinweis |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Erkrankungen | DIS-HCL |
| Quellen | SRC-ESMO-DLBCL-2024 SRC-NCCN-BCELL-2025 |
Ursprung der Roten Flagge
| Begriffsbestimmung | Age >75 + ECOG ≥2 OR significant comorbidity — pentostatin's weekly schedule allows finer toxicity titration than cladribine 5-7 day continuous infusion; preferred for fragile patients. |
|---|---|
| Klinische Richtung | Eskalation |
| Kategorie | Gebrechlichkeit |
| Schaltet Algorithmus | ALGO-HCL-1L |
Logik auslösen
{
"all_of": [
{
"any_of": [
{
"comparator": ">",
"finding": "age_years",
"threshold": 75
},
{
"comparator": ">=",
"finding": "comorbidity_count",
"threshold": 2
}
]
},
{
"comparator": ">=",
"finding": "ecog_status",
"threshold": 2
}
],
"type": "composite_clinical"
}
Anmerkungen
Pentostatin's weekly cadence permits adjustment between doses; cladribine's 5-7-day infusion is committed. For elderly frail, pentostatin's tolerability advantage outweighs cladribine's slightly higher CR rate.
Verwendet von
Algorithmen
ALGO-HCL-1L- ALGO-HCL-1LALGO-HCL-2L- ALGO-HCL-2L
Anwendungsgebiet
IND-HCL-2L-VEMURAFENIB- IND-HCL-2L-VEMURAFENIB